苦杏仁酸鈣 | 134-95-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 苦杏仁酸鈣
• 中文别名: 苯乙醇酸鈣；苦杏仁酸?
• 英文名称: Benzeneacetic acid, a-hydroxy-, calcium salt (2:1)
• CAS: 134-95-2
• 化学式: C8H8CaO3
• 分子量: 192.22
• InChiKey: VZUDGLMLVNVCHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.42
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• COOLANT COMPOSITION
  申请人：Shishiai-Kabushikigaisha

  公开号：EP2003182A9

  公开（公告）日：2009-04-08

  The present invention relates to a coolant composition having an excellent corrosion control function, mainly for metals which form cooling systems for internal combustion engines and the like, particularly aluminum or aluminum alloys, where the excellent corrosion control function for aluminum or aluminum alloys is not deteriorated even when mixed with a cooling composition containing another component, and is characterized by having a glycol as a base and containing (a) 0.05 to 0.5 mass % of silicic acid or an alkali metal salt thereof; (b) 0.5 to 5 mass % of p-tert-butyl benzoic acid or an alkali metal salt thereof; (c) 0.1 to 0.8 mass % of sebacic acid or an alkali metal salt thereof; (d) 0.001 to 0.5 mass % of at least one type selected from among strontium compounds, magnesium compounds and calcium compounds; and (e) 0.05 to 1.0 mass % of a triazole.

  本发明涉及一种具有优异腐蚀控制功能的冷却剂组合物，主要用于构成内燃机等冷却系统的金属，特别是铝或铝合金，即使与含有另一种成分的冷却组合物混合，铝或铝合金的优异腐蚀控制功能也不会降低，其特征在于以乙二醇为基质，并含有 (a) 0.05 至 0.5 质量％的硅酸或其碱金属盐；(b) 0.5 至 5 质量％的对叔丁基苯甲酸或其碱金属盐；(c) 0.(a) 0.05 至 0.5 质量百分比的硅酸或其碱金属盐；(b) 0.5 至 5 质量百分比的对叔丁基苯甲酸或其碱金属盐；(c) 0.1 至 0.8 质量百分比的癸二酸或其碱金属盐；(d) 0.001 至 0.5 质量百分比的至少一种选自锶化合物、镁化合物和钙化合物的类型；以及 (e) 0.05 至 1.0 质量百分比的三唑。
• COOLING LIQUID COMPOSITION
  申请人：Shishiai-Kabushikigaisha

  公开号：EP2554621A1

  公开（公告）日：2013-02-06

  Disclosed is a cooling liquid composition, which has an excellent ability to prevent the corrosion of mainly a metal constituting a cooling system for an internal combustion engine or the like, particularly an iron-based metal, or alumninum or an aluminum alloy, and also can effectively inhibit cavitation damage. The composition contains a glycol as a base material, wherein the composition does not contain p-tert butyl benzoate or an alkali metal salt thereof, but contains (a) 0.05-0.5% by mass of silicic acid or an alkali metal salt thereof, (b) 0.1-8% by mass of sebacic acid or an alkali metal salt thereof, (c) 0.1-10% by mass of toluic acid or an alkali metal salt thereof, and (d) 0.001-0.5% by mass of at least one compound selected from a strontium compound, a magnesium compound, and a calcium compound.

  本发明公开了一种冷却液组合物，该组合物对主要构成内燃机或类似设备冷却系统的金属（尤其是铁基金属、铝或铝合金）具有出色的防腐蚀能力，还能有效抑制气蚀破坏。该组合物含有乙二醇作为基础材料，其中该组合物不含对叔丁基苯甲酸酯或其碱金属盐，但含有 (a) 0.05-0.5% 质量百分比的硅酸或其碱金属盐，(b) 0.1-8%（质量百分比）的癸二酸或其碱金属盐，(c) 0.1-10%（质量百分比）的甲苯酸或其碱金属盐，以及 (d) 0.001-0.5%（质量百分比）的至少一种选自锶化合物、镁化合物和钙化合物的化合物。
• THERMOPLASTIC POLYMER COMPOSITION
  申请人：Milliken & Company

  公开号：EP2488579A1

  公开（公告）日：2012-08-22
• Methods and devices for the treatment of ocular conditions
  申请人：deJuan Eugene

  公开号：US20060110428A1

  公开（公告）日：2006-05-25

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.